Monday, August 31, 2026

Moderna Stock Bearish By 3% So Far On Tuesday

ViaNews Editorial Team

December 15, 2020

Moderna Stock Bearish By 3% So Far On Tuesday

Shares of Moderna fell 3.25% to $150.03 at 11:10 EST on Tuesday, following yesterday's downward trend. The Nasdaq Stock Market is jumping 0.74% to $12,532.50, following yesterday's upward trend, This seems, so far, a somewhat positive trend exchanging session today.

Moderna's last close was $155.07, 18.98% below its 52-week high of $178.50.

News about Moderna today

Take-two, occidental petroleum, Moderna: what to watch when the stock market opens today. According to today's article on The Wall Street Journal, "-Shares of the vaccine maker Moderna were down 1% premarket. "

Moderna vaccine found safe, effective ahead of key FDA review. According to today's article on Bloomberg Quint, "Once the U.S. grants authorization, advisers to the Centers for Disease Control and Prevention must meet, as they did last week on Pfizer's vaccine, to give Moderna's shot the green light and provide offer specific recommendations for use and monitoring. ", "The shot must be kept extremely cold and requires special freezers to transport, while Moderna's can be kept in more traditional cold storage."

Moderna vaccine found safe, effective before key FDA review. According to today's article on Bloomberg Quint, "In addition, there were two cases of serious facial swelling in vaccine recipients that Moderna determined were related to vaccination. ", "The shot must be kept extremely cold and requires special freezers to transport, while Moderna's can be kept in more traditional cold storage."

Moderna shares up in premarket as FDA calls covid-19 vaccine 'highly effective'. According to today's article on MarketWatch, "Shares of Moderna Inc. gained 1.5% in premarket trading on Tuesday after the Food and Drug Administration said the company's COVID-19 vaccine candidate is "highly effective" at preventing infections with the coronavirus. "

Moderna's Sales

Moderna's sales growth is 1428.1% for the present quarter and 13065.3% for the next. The company's growth estimates for the current quarter is a negative 48.6% and positive 565.7% for the next.

Moderna's Revenue

Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.

Moderna's Stock Top and Bottom Yearly Value

Moderna's stock is valued at $150.03 at 11:10 EST, way below its 52-week high of $178.50 and way above its 52-week low of $17.68.

Moderna's Moving Average

Moderna's value is way above its 50-day moving average of $106.15 and way higher than its 200-day moving average of $77.98.

Previous days news about Moderna

Moderna offers U.S. fail-safe on vaccines if Pfizer falls short. According to Bloomberg Quint on Thu Dec 10, "If the U.S. doesn't lock in the full 400 million extra doses, it could free up capacity for Moderna to sell more supply to other countries, potentially at a higher price.", "If it reaches the higher end of that range, Moderna could meet most of the U.S. demand for a coronavirus vaccine, Morgan Stanley analyst Matthew Harrison said in a note to clients on Dec. 8."

Moderna says U.S. to buy 100 million additional vaccine doses. According to Bloomberg Quint on Fri Dec 11, "Moderna said Friday that the order, worth $1.65 billion, would be delivered during the second quarter of 2021. ", "As part of Operation Warp Speed, the U.S. initiative to rapidly develop and secure vaccines for Covid-19, the U.S. has the option to buy another 300 million doses from Moderna at a fixed price of $16.50 per shot, the company said. "

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI's Trust Gap: Microsoft-Mistral Ecosystem Expansion Meets a Governance Deficit in Agentic Adoption
Microsoft is deepening its AI platform bet through simultaneous moves — expanding its Mistral partnership (Copilot Studio, Foundry, European infrastructure capacity) and deepening enterprise AI governance ties with Manulife — just as independent research (Google Cloud, VentureBeat, Box) shows enterprises racing toward agentic AI adoption (100% planned within two years) while data access and trust in agent decisions lag badly (average 45% data access, only ~half trust agent outputs). The result is a structural mismatch between platform-vendor momentum and enterprise readiness to actually govern and trust the agents being deployed.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
Same entity (Morgan Stanley & Co. LLC), same metric (net_income), same fiscal period (Q1 2026), same observation date (2026-03-31), but vastly different values: $5.567 billion vs. $5.57. These cannot coexist for the same time period. Fact B appears to be a data entry error (possible missing decimal placement: 5.57 should likely be 5,567,000,000 or a per-share figure incorrectly entered as total).
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,257 source documents archived
Query this data → isubstrate.com